Filing Flows › Acadia Pharmaceuticals (ACAD) › Q4 2025
Acadia Pharmaceuticals (ACAD) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Acadia Pharmaceuticals (ACAD) reported revenue of $284M for the fourth quarter 2025 (Q4 2025), +9% from a year earlier and +2% from the quarter before. Operating margin was 6.1%, net earnings $274M (96.3% of revenue).
Acadia Pharmaceuticals, Q4 2025: revenue $284M (+9% year over year), operating margin 6.1%, net earnings $274M, operating cash flow −$48.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $284M | +2% | +9% |
| Operating profit | $17.4M | -51% | -89% |
| Net earnings | $274M | +281% | +90% |
| Operating cash flow | −$48.7M | -166% | — |
What changed
Revenue was $284.0M in Q4 2025, up 9% year over year and up 2% from the previous quarter.
Operating profit was $17.4M, a 6.1% margin (down 53.0 points year over year). Operating profit fell $136.1M even though revenue rose $24.4M versus a year earlier, so costs grew faster than sales. Total costs grew 151% against revenue growth of 9%. Net earnings were $273.6M, up 90% year over year. The tax line was a benefit of $247.2M on pre-tax earnings of $26.3M. Non-operating items added $8.9M, 34% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$48.7M. Non-cash charges added back $2.9M of depreciation and amortization and $13.2M of share-based compensation. Working capital and other items used $338.5M. Capital expenditures of $4.0M exceeded it, leaving free cash flow of −$52.7M.
Questions
What was Acadia Pharmaceuticals' revenue in the fourth quarter 2025?
Acadia Pharmaceuticals (ACAD) reported revenue of $284M for the fourth quarter 2025 (Q4 2025), +9% from a year earlier and +2% from the quarter before.
Was Acadia Pharmaceuticals profitable in the fourth quarter 2025?
Operating profit was $17.4M (6.1% of revenue) and net earnings $274M.